Evidence map›Paper›PMID 39605750›Full record

ArticleFrontiers in bioengineering and biotechnology2024

Magnetically driven hydrogel microrobots for enhancing the therapeutic effect of anlotinib on osteosarcoma.

Haoyu Wang, Haitian Jiang, Yining Tao, Binghui Yang, Jiakang Shen, Haoran Mu, Chongren Wang, Xiyu Yang, Zhengdong Cai, Mu Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Embodied Cross-Domain Intelligence in Biomedical Microrobots: A Review.Cyborg and bionic systems (Washington, D.C.) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Haoyu WangDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Haitian JiangState Key Laboratory of Robotics and System, Harbin Institute of Technology, Harbin, China.
Yining TaoDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Binghui YangDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jiakang ShenDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Haoran MuDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chongren WangDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiyu YangDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhengdong CaiDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Mu LiDepartment of Pharmacy, Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, China.
Wei SunDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Liu YangDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Mengxiong SunDepartment of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Osteosarcoma, characterized by high mortality and disability rates, poses a significant challenge due to its complex genetic background and the absence of specific membrane receptors, which hinder effective targeted therapy. Active targeting has emerged as a promising approach to address this issue. Methods: In this study, magnetically driven hydrogel robots (MMHR) were utilized to load and deliver drugs precisely to target sites. The drugs included SCR1481B16, a specific MET inhibitor proven to inhibit MET-driven tumor growth, and Anlotinib. The microrobots were designed to navigate under magnetic guidance, enhancing drug efficacy while minimizing damage to normal tissues. Results: The study explored the potential of MMHR loaded with SCR1481B16 and Anlotinib in the treatment of Anlotinib-resistant osteosarcoma. The microrobots were successfully designed and produced, demonstrating the ability to deliver drugs precisely to tumor sites. Evaluation of the microrobots showed an enhanced sensitivity of tumors to Anlotinib, providing new insights into the treatment of drug-resistant osteosarcoma. Discussion: Tumors overexpressing MET often develop resistance to VEGFR-targeted drugs. The use of SCR1481B16 as a MET inhibitor in combination with Anlotinib, delivered by magnetically driven hydrogel microrobots, offers a novel strategy to overcome this resistance. However, further in-depth research and validation are required before the clinical application of this method can be considered. Conclusion: In conclusion, magnetically driven hydrogel microrobots loaded with SCR1481B16 provide a promising new strategy for enhancing the sensitivity of Anlotinib-resistant osteosarcoma, bringing hope for future clinical applications in the treatment of this challenging disease.

Indexed as

drug delivery systemmagnetic-drivenmetmicrorobotsosteosarcomaVEGFR

Identifiers

PMID39605750
PMCPMC11600141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.